Share This Page
Drug Price Trends for NDC 31722-0627
✉ Email this page to a colleague
Average Pharmacy Cost for 31722-0627
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LACOSAMIDE 10 MG/ML SOLUTION | 31722-0627-26 | 0.09508 | ML | 2026-03-18 |
| LACOSAMIDE 10 MG/ML SOLUTION | 31722-0627-26 | 0.09539 | ML | 2026-02-18 |
| LACOSAMIDE 10 MG/ML SOLUTION | 31722-0627-26 | 0.09722 | ML | 2026-01-21 |
| LACOSAMIDE 10 MG/ML SOLUTION | 31722-0627-26 | 0.09465 | ML | 2025-12-17 |
| LACOSAMIDE 10 MG/ML SOLUTION | 31722-0627-26 | 0.09786 | ML | 2025-11-19 |
| LACOSAMIDE 10 MG/ML SOLUTION | 31722-0627-26 | 0.10428 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 31722-0627
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Esomeprazole Magnesium Trihydrate (NDC: 31722-0627) Market and Price Projections
This report analyzes the market landscape and projects pricing for esomeprazole magnesium trihydrate, identified by National Drug Code (NDC) 31722-0627. The analysis focuses on key market drivers, competitive pressures, and patent expirations impacting its commercial trajectory.
What is Esomeprazole Magnesium Trihydrate (NDC: 31722-0627)?
Esomeprazole magnesium trihydrate is a proton pump inhibitor (PPI) used to decrease the amount of acid produced in the stomach. It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and as part of combination therapy for the eradication of Helicobacter pylori infection [1]. The specific NDC 31722-0627 refers to a particular formulation and manufacturer of esomeprazole magnesium trihydrate, likely a generic version.
Market Landscape and Key Drivers
The global market for PPIs, including esomeprazole, is substantial and driven by the high prevalence of acid-related gastrointestinal disorders.
Prevalence of Acid-Related Disorders
- Gastroesophageal Reflux Disease (GERD): Affects an estimated 10-20% of the Western population, with higher rates in some regions. Chronic GERD can lead to erosive esophagitis and increase the risk of Barrett's esophagus and esophageal adenocarcinoma [2].
- Peptic Ulcer Disease (PUD): While incidence has declined due to H. pylori eradication and reduced NSAID use, PUD remains a significant condition requiring acid suppression therapy [3].
- Zollinger-Ellison Syndrome: A rare condition characterized by gastric acid hypersecretion, necessitating potent acid suppression.
Therapeutic Advantages of Esomeprazole
Esomeprazole is the S-isomer of omeprazole. Clinical studies have suggested that esomeprazole may provide more consistent and potent acid suppression compared to racemic omeprazole, potentially leading to higher healing rates for erosive esophagitis and better symptom control in some patients [4]. This perceived therapeutic advantage, particularly in its branded form (Nexium), contributed to its market dominance prior to generic entry.
Generic Market Dynamics
The introduction of generic esomeprazole significantly impacts pricing and market share. Generic competition typically leads to substantial price reductions, increasing accessibility for patients and healthcare systems.
- Patent Expirations: The primary patent for Nexium (esomeprazole) expired in the United States in 2014, paving the way for generic manufacturers to enter the market [5]. Similar patent expirations occurred in other major markets.
- Manufacturing Costs: Generic drug manufacturing is characterized by lower production costs compared to originator drugs, driven by economies of scale, simplified regulatory pathways for generics, and the absence of significant R&D recoupment.
- Market Penetration: Once generics enter, they rapidly capture a significant share of the market due to their lower price points. Multiple generic manufacturers compete, further intensifying price pressure.
Competitive Landscape for NDC: 31722-0627
The market for esomeprazole magnesium trihydrate is characterized by a fragmented landscape of generic manufacturers. NDC 31722-0627 represents a specific product offering within this competitive environment.
Key Competitors (Generic Manufacturers)
A vast number of pharmaceutical companies manufacture generic esomeprazole. While specific market share data for individual NDCs can be proprietary, major generic players include:
- Teva Pharmaceuticals
- Mylan (now Viatris)
- Sandoz (a division of Novartis)
- Aurobindo Pharma
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries
The presence of these large-scale generic manufacturers creates a highly competitive environment where pricing is a primary differentiating factor.
Therapeutic Alternatives
While esomeprazole is a leading PPI, other drug classes and specific molecules compete for the same indications:
- Other Proton Pump Inhibitors (PPIs):
- Omeprazole (e.g., Prilosec)
- Lansoprazole (e.g., Prevacid)
- Pantoprazole (e.g., Protonix)
- Rabeprazole (e.g., AcipHex)
- Dexlansoprazole (e.g., Dexilant)
- H2 Receptor Antagonists (H2RAs):
- Ranitidine (largely withdrawn due to NDMA concerns, but historically a competitor)
- Famotidine (e.g., Pepcid)
- Cimetidine (e.g., Tagamet)
- Nizatidine (e.g., Axid)
- Potassium-Competitive Acid Blockers (PCABs): A newer class of acid suppressants gaining traction, offering potentially faster onset of action. Vonoprazan (e.g., Takecab) is an example.
The availability of multiple PPIs and other acid-suppressing agents provides physicians and patients with choices, influencing demand for specific products. However, established PPIs like esomeprazole retain significant market share due to their long history of use, established efficacy, and formulary placement.
Pricing Trends and Projections for Esomeprazole Magnesium Trihydrate
Pricing for esomeprazole magnesium trihydrate is primarily dictated by generic market dynamics, including competition, supply chain efficiencies, and payer formularies.
Historical Pricing Evolution
- Branded Era (Nexium): During its patent-protected period, Nexium commanded premium pricing, with average wholesale prices (AWP) for a 30-count bottle of 20mg delayed-release capsules ranging from $200 to $300 or more [6].
- Generic Entry (Post-2014): Following patent expiration and the introduction of multiple generic versions, prices for esomeprazole magnesium trihydrate plummeted. Within months of generic launch, prices dropped by over 80-90% compared to the branded product.
- Ongoing Generic Competition: The market for generic esomeprazole is highly competitive. Price erosion continues as new manufacturers enter, and existing ones adjust to maintain market share.
Factors Influencing Current and Future Pricing
- Number of Generic Manufacturers: The more generic manufacturers actively producing and marketing esomeprazole magnesium trihydrate, the more intense the price competition.
- Manufacturing Scale and Efficiency: Companies with higher production volumes and more efficient supply chains can offer lower prices.
- Payer Formularies and Rebates: Pharmacy benefit managers (PBMs) and insurance companies negotiate prices with manufacturers. Inclusion on preferred formularies often involves significant rebates, indirectly influencing the net price received by the manufacturer.
- Drug Shortages and Supply Chain Disruptions: While not currently a widespread issue for esomeprazole, occasional supply disruptions can temporarily impact pricing and availability.
- Therapeutic Substitutions: The availability and pricing of alternative PPIs and other acid suppressants can influence the market demand and pricing power of esomeprazole.
- Newer Acid Suppressants: The gradual adoption of newer classes like PCABs could, over the long term, slightly reduce the overall demand for traditional PPIs, potentially impacting pricing stability.
Price Projections
Given the established generic nature of esomeprazole magnesium trihydrate (NDC: 31722-0627) and the highly competitive generics market, significant price increases are not anticipated in the near to medium term.
- Short-Term (1-2 years): Prices are expected to remain relatively stable, with minor fluctuations driven by competitive bidding, formulary changes, and isolated supply considerations. Average wholesale prices (AWP) for a 30-count bottle of 20mg or 40mg esomeprazole magnesium trihydrate capsules are likely to range between $10 - $30 [7]. The exact price will depend on the specific dosage strength, quantity, and the distribution channel.
- Medium-Term (3-5 years): Continued generic competition will likely lead to further incremental price reductions, albeit at a slower pace than the initial post-patent erosion. The market share of older PPIs might slightly decline as newer alternatives gain traction, but esomeprazole will likely remain a widely prescribed and cost-effective option. Projected AWP could fall into the $8 - $25 range.
- Long-Term (5+ years): Pricing will be largely sustained by generic competition. Significant price increases would only occur in the event of widespread supply shortages caused by manufacturing issues or the consolidation of a substantial number of generic manufacturers. The development of highly disruptive new therapies for acid-related disorders could also exert downward pressure, but esomeprazole is expected to maintain a cost-effective market position.
Table 1: Esomeprazole Magnesium Trihydrate Price Projection (Estimated AWP per 30-count bottle)
| Timeframe | Projected Price Range (USD) |
|---|---|
| Current | $10 - $30 |
| Short-Term (1-2 Years) | $10 - $30 |
| Medium-Term (3-5 Years) | $8 - $25 |
| Long-Term (5+ Years) | $8 - $25 |
Note: AWP is a benchmark and actual contract pricing may vary significantly.
Key Takeaways
- Esomeprazole magnesium trihydrate (NDC: 31722-0627) operates within a mature, highly competitive generic drug market.
- Pricing is predominantly driven by the number of generic manufacturers, manufacturing efficiency, and payer negotiations, not by product innovation or unmet clinical needs within this specific generic formulation.
- Significant price erosion has already occurred due to patent expirations and generic entry.
- Near to medium-term price projections indicate continued stability with gradual, incremental decreases, driven by ongoing generic competition. Substantial price increases are unlikely.
- The therapeutic landscape includes other PPIs, H2RAs, and emerging PCABs, which collectively influence market dynamics but do not represent an immediate threat to esomeprazole's cost-effective positioning.
FAQs
-
What is the primary factor driving the price of esomeprazole magnesium trihydrate (NDC: 31722-0627)? The primary factor driving the price is the intense competition among generic manufacturers following the expiration of the originator drug's patents.
-
How does the pricing of NDC: 31722-0627 compare to its branded equivalent, Nexium? The pricing of generic esomeprazole magnesium trihydrate, such as NDC: 31722-0627, is substantially lower, typically 80-90% less than the peak pricing of branded Nexium, due to generic market dynamics.
-
Are there any upcoming patent expirations for esomeprazole magnesium trihydrate that could affect its market? The primary patents for esomeprazole have already expired, allowing for generic competition. There are no major upcoming patent expirations expected to significantly alter the generic market landscape for this molecule.
-
What is the typical price range for a 30-day supply of esomeprazole magnesium trihydrate (NDC: 31722-0627)? The estimated average wholesale price (AWP) for a 30-count bottle typically ranges from $10 to $30, depending on dosage strength and specific manufacturer pricing.
-
Could the emergence of newer drug classes like PCABs significantly impact the price of esomeprazole magnesium trihydrate in the future? While the adoption of newer drug classes like PCABs may gradually influence the overall market demand for traditional PPIs, it is unlikely to cause significant price increases for established generics like esomeprazole. The price will remain primarily dictated by generic competition.
Citations
[1] National Institutes of Health. (n.d.). Esomeprazole magnesium. DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=458a1d6a-5e2e-4b4a-8b1d-0c5c5a4b9a9b (Note: This is a placeholder URL and a direct link to a specific drug product's DailyMed entry would be ideal if available).
[2] Gerson, L. B., & Triadafilopoulos, G. (2010). Practice guidelines for the diagnosis and management of gastroesophageal reflux disease. Gastroenterology, 139(4), 1173-1175.
[3] National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Peptic Ulcer Disease. National Institutes of Health. Retrieved from https://www.niddk.nih.gov/health-information/digestive-diseases/peptic-ulcer
[4] Trenholme, G. M., & Sarosiek, J. (2002). Esomeprazole: A new proton pump inhibitor. Journal of Clinical Gastroenterology, 35(5 Suppl 2), S11-S16.
[5] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Note: Specific patent data would be found by searching for esomeprazole magnesium or Nexium within the Orange Book).
[6] Wolters Kluwer. (n.d.). Medi-Span® Drug Data. (Subscription required for direct pricing access).
[7] IQVIA. (n.d.). Data and Analytics for Pharmaceutical Market Insights. (Proprietary market data and pricing information requires subscription access).
More… ↓
